Versameb moves forward with its lead asset towards clinical development with an Innovative synthetic doggybone DNA technology which increases quality and yield of mRNA therapeutics production Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a development and manufacturing pipeline agreement with Versameb AG, an innovative pre-clinical stage […]
Data published in the Journal of ImmunoTherapy of Cancer confirms efficacy of combination treatment (ISA101b + anti-PD1) Deep and durable responses have a profound positive effect on patient prognosis with patients disease-free for more than 44 months Improved tumour infiltration by immune cells predicted response to therapy Oegstgeest, March 1, 2022 – ISA today announces the publication of […]
Funds will accelerate wide-scale adoption and commercialisation of biocement® technology Supports goal to eliminate 25% of global carbon emissions from the concrete industry by 2030 Copenhagen, Denmark – 28 February 2022 – Novo Holdings, a leading international life sciences investor, today announces it has participated in the US$65 million Series C financing in Biomason, the only […]
February 24, 2022 Stockholm, Sweden, February 24, 2022 – Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today launched #MCT8Hugs – a global, online initiative to drive awareness of MCT8 deficiency. MCT8 deficiency is a rare and life-shortening genetic disease, causing serious consequences such as severely impaired neurocognitive development and motor function. In most of those […]
Appointment of experts to support development of lead candidate VMB-100, an RNA-based therapy for Stress Urinary Incontinence Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, today announces the formation of an Advisory Board comprised of industry leaders in urology. These include Professor Roger Dmochowski of Vanderbilt University, Professor Margot Damaser of the […]
